Saxenda is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Liraglutide.
| Product ID | 0169-2800_22354b1e-31ba-4cad-974e-3620604d2f6d |
| NDC | 0169-2800 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Saxenda |
| Generic Name | Liraglutide |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2014-12-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA206321 |
| Labeler Name | Novo Nordisk |
| Substance Name | LIRAGLUTIDE |
| Active Ingredient Strength | 6 mg/mL |
| Pharm Classes | GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2015-01-19 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA206321 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2015-01-19 |
| Marketing Category | NDA |
| Application Number | NDA206321 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2015-01-19 |
| Marketing Category | NDA |
| Application Number | NDA206321 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2015-01-19 |
| Ingredient | Strength |
|---|---|
| LIRAGLUTIDE | 6 mg/mL |
| SPL SET ID: | 3946d389-0926-4f77-a708-0acb8153b143 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0169-2800 | Saxenda | liraglutide |
| 50090-4257 | Saxenda | liraglutide |
| 0169-4060 | Victoza | liraglutide |
| 50090-2853 | Victoza | liraglutide |
| 50090-4503 | Victoza | liraglutide |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() SAXENDA 79141628 4541356 Live/Registered |
Novo Nordisk A/S 2013-10-25 |